Baseline features and eradication strategies in the AHASR patients stratified according to the occurrence of all-cause fatalities
| Variable . | All-cause exitus . | P . | |
|---|---|---|---|
| Yes (N = 36) | No (N = 115) | ||
| Age at Dx (y), median (IQR) | 79 (73-87) | 73 (62-80) | <.001 |
| Sex (male), n/N (%) | 22/35 (62.9) | 61/113 (54.0) | .437 |
| Follow-up (months)*, median (IQR) | 2.7 (1.0-19.0) | 15.0 (4.0-36.0) | .001 |
| FVIII:C (%) at Dx, median (IQR) | 2.0 (0.3-5.2) | 1.9 (0.9-4.7) | .899 |
| FVIII:C (%) <1%, n/N (%) | 10/33 (30.3) | 27/99 (27.3) | .449 |
| Inhibitor at Dx, median (IQR) | 16.50 (7.37-49.20) | 16.00 (4.14-42.40) | .607 |
| Antithrombotic therapy†, n/N (%) | 14/36 (38.9) | 17/115 (14.8) | .003 |
| Underlying disease‡ | |||
| Idiopathic, n/N (%) | 11/35 (31.4) | 51/111 (45.9) | .170 |
| Autoimmune, n/N (%) | 12/35 (34.3) | 29/111 (26.1) | .391 |
| Neoplasia, n/N (%) | 5/35 (14.3) | 10/111 (9.0) | .355 |
| Postpartum, n/N (%) | 0/35 (0) | 9/111 (8.1) | .115 |
| Other, n/N (%) | 8/35 (22.9) | 15/111 (13.5) | .192 |
| Immunosuppressive therapy | |||
| Steroids, n/N (%) | 7/36 (19.4) | 20/108 (18.5) | 1.000 |
| Steroids + CFX, n/N (%) | 14/36 (38.9) | 49/108 (45.4) | .563 |
| Steroids + CNI, n/N (%) | 6/36 (16.7) | 11/108 (10.2) | .370 |
| Rituximab-based regimens, n/N (%) | 8/36 (22.2) | 24/108 (22.2) | 1.000 |
| No eradication treatment, n/N (%) | 1/36 (2.8) | 4/108 (3.7) | 1.000 |
| CR, n/N (%) | 25/34 (73.5) | 84/96 (87.5) | .100 |
| Days until CR, median (IQR) | 38 (24-59) | 49 (30-87) | .163 |
| Variable . | All-cause exitus . | P . | |
|---|---|---|---|
| Yes (N = 36) | No (N = 115) | ||
| Age at Dx (y), median (IQR) | 79 (73-87) | 73 (62-80) | <.001 |
| Sex (male), n/N (%) | 22/35 (62.9) | 61/113 (54.0) | .437 |
| Follow-up (months)*, median (IQR) | 2.7 (1.0-19.0) | 15.0 (4.0-36.0) | .001 |
| FVIII:C (%) at Dx, median (IQR) | 2.0 (0.3-5.2) | 1.9 (0.9-4.7) | .899 |
| FVIII:C (%) <1%, n/N (%) | 10/33 (30.3) | 27/99 (27.3) | .449 |
| Inhibitor at Dx, median (IQR) | 16.50 (7.37-49.20) | 16.00 (4.14-42.40) | .607 |
| Antithrombotic therapy†, n/N (%) | 14/36 (38.9) | 17/115 (14.8) | .003 |
| Underlying disease‡ | |||
| Idiopathic, n/N (%) | 11/35 (31.4) | 51/111 (45.9) | .170 |
| Autoimmune, n/N (%) | 12/35 (34.3) | 29/111 (26.1) | .391 |
| Neoplasia, n/N (%) | 5/35 (14.3) | 10/111 (9.0) | .355 |
| Postpartum, n/N (%) | 0/35 (0) | 9/111 (8.1) | .115 |
| Other, n/N (%) | 8/35 (22.9) | 15/111 (13.5) | .192 |
| Immunosuppressive therapy | |||
| Steroids, n/N (%) | 7/36 (19.4) | 20/108 (18.5) | 1.000 |
| Steroids + CFX, n/N (%) | 14/36 (38.9) | 49/108 (45.4) | .563 |
| Steroids + CNI, n/N (%) | 6/36 (16.7) | 11/108 (10.2) | .370 |
| Rituximab-based regimens, n/N (%) | 8/36 (22.2) | 24/108 (22.2) | 1.000 |
| No eradication treatment, n/N (%) | 1/36 (2.8) | 4/108 (3.7) | 1.000 |
| CR, n/N (%) | 25/34 (73.5) | 84/96 (87.5) | .100 |
| Days until CR, median (IQR) | 38 (24-59) | 49 (30-87) | .163 |